Cargando…
Glucose variability: a new risk factor for cardiovascular disease
AIMS AND DATA SYNTHESIS: Glucose variability (GV) is increasingly considered an additional index of glycemic control. Growing evidence indicates that GV is associated with diabetic vascular complications, thus being a relevant point to address in diabetes management. GV can be measured using various...
Autores principales: | Belli, Martina, Bellia, Alfonso, Sergi, Domenico, Barone, Lucy, Lauro, Davide, Barillà, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442283/ https://www.ncbi.nlm.nih.gov/pubmed/37341768 http://dx.doi.org/10.1007/s00592-023-02097-w |
Ejemplares similares
-
Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
por: Belli, Martina, et al.
Publicado: (2022) -
Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?
por: Belli, Martina, et al.
Publicado: (2023) -
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
por: Prandi, Francesca Romana, et al.
Publicado: (2022) -
Prevalence of Cardiovascular Risk Factors and Coronary Angiographic Findings in High-Risk Immigrant Communities in Italy
por: Muscoli, Saverio, et al.
Publicado: (2023) -
The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
por: Muscoli, Saverio, et al.
Publicado: (2022)